Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Éva Compérat, Mahul B. Amin, Richard Cathomas, et al.
The Lancet (2022) Vol. 400, Iss. 10364, pp. 1712-1721
Open Access | Times Cited: 211

Showing 1-25 of 211 citing articles:

Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
Ibrahim Jubber, Sean Ong, Laura Bukavina, et al.
European Urology (2023) Vol. 84, Iss. 2, pp. 176-190
Open Access | Times Cited: 206
Bladder cancer
Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 153
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis
Alexandre R. Zlotta, Leslie Ballas, Andrzej Niemierko, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. 669-681
Closed Access | Times Cited: 118
European cancer mortality predictions for the year 2023 with focus on lung cancer
Matteo Malvezzi, Claudia Santucci, Paolo Boffetta, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 410-419
Open Access | Times Cited: 92
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms
Fei Li, Zaosong Zheng, Wei Chen, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100938-100938
Closed Access | Times Cited: 87
miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay – A review
Hesham A. El-Mahdy, Elsayed G.E. Elsakka, Ahmed A. El-Husseiny, et al.
Pathology - Research and Practice (2023) Vol. 242, pp. 154316-154316
Closed Access | Times Cited: 59
From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression
Riya Thapa, Obaid Afzal, Muhammad Afzal, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 154959-154959
Closed Access | Times Cited: 48
European cancer mortality predictions for the year 2024 with focus on colorectal cancer
Claudia Santucci, Silvia Mignozzi, Matteo Malvezzi, et al.
Annals of Oncology (2024) Vol. 35, Iss. 3, pp. 308-316
Open Access | Times Cited: 43
A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance
Yi Lei, Xin Jiang, Zaigang Zhou, et al.
Advanced Materials (2024) Vol. 36, Iss. 15
Closed Access | Times Cited: 24
Molecular profile of bladder cancer progression to clinically aggressive subtypes
Charles C. Guo, Sangkyou Lee, June G. Lee, et al.
Nature Reviews Urology (2024) Vol. 21, Iss. 7, pp. 391-405
Closed Access | Times Cited: 24
CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis
Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 2, pp. 277-287
Open Access | Times Cited: 15
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer
Tianlei Xie, Shan Peng, Shujun Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer
Guangdi Chu, Xiaoyu Ji, Yonghua Wang, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 33, pp. 110-126
Open Access | Times Cited: 38
Targeting DNA Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate STING Pathway for Maximizing Chemo‐Immunotherapy in Bladder Cancer
Wenkuan Wang, Feiya Yang, Lingpu Zhang, et al.
Advanced Materials (2023) Vol. 36, Iss. 1
Closed Access | Times Cited: 28
M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription
Jinbo Xie, Hui Zhang, Keyi Wang, et al.
Oncogene (2023) Vol. 42, Iss. 40, pp. 2956-2970
Open Access | Times Cited: 24
Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence
Tobechukwu Okobi, Trinitas Oserefuamen Uhomoibhi, Darlington E Akahara, et al.
Cureus (2023)
Open Access | Times Cited: 22
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis
Jiahe Yi, Xueyou Ma, Yufan Ying, et al.
Cancer Letters (2024) Vol. 585, pp. 216613-216613
Open Access | Times Cited: 11
Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement
Emily Gill, Claire M. Perks
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1557-1557
Open Access | Times Cited: 10
Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder Cancer
Kangkang Liu, Lining Wang, Jing Peng, et al.
Advanced Materials (2024) Vol. 36, Iss. 19
Closed Access | Times Cited: 10
Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1
Shuangjie Liu, Xialu Wang, Xiaojie Sun, et al.
Phytomedicine (2024) Vol. 126, pp. 155426-155426
Closed Access | Times Cited: 7
TGF-β1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells
Qinrong Ping, Chunhui Wang, Xin Cheng, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Seizing the fate of lymph nodes in immunotherapy: To preserve or not?
Zhenyu Xu, Zi‐Zhan Li, Lei‐Ming Cao, et al.
Cancer Letters (2024) Vol. 588, pp. 216740-216740
Closed Access | Times Cited: 6
Knockdown of integrin β1 inhibits proliferation and promotes apoptosis in bladder cancer cells
Jin‐feng Wang, Jianshe Wang, Yang Liu, et al.
BioFactors (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 6
Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications
Emanuela Germanà, Ludovica Pepe, Cristina Pizzimenti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6750-6750
Open Access | Times Cited: 5
Combined Inhibition of PI3K and STAT3 signaling effectively inhibits bladder cancer growth
Weidong Peng, Haojie Zhang, Mingwei Yin, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top